Research Output per year
Fingerprint Dive into the research topics where Gian Carlo Antonini Cappellini is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Melanoma
Medicine & Life Sciences
Neutrophils
Medicine & Life Sciences
Lymphocytes
Medicine & Life Sciences
Biomarkers
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Eosinophils
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2000 2019
3
Citations
(Scopus)
MiR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
Caporali, S., Amaro, A., Levati, L., Alvino, E., Lacal, P. M., Mastroeni, S., Ruffini, F., Bonmassar, L., Antonini Cappellini, G. C., Felli, N., Carè, A., Pfeffer, U. & D'Atri, S., Jun 21 2019, In : Journal of Experimental and Clinical Cancer Research. 38, 1, 272.Research output: Contribution to journal › Article
Open Access
Vascular Endothelial Growth Factor A
Melanoma
Down-Regulation
MicroRNAs
Immunoblotting
1
Citation
(Scopus)
Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386
on behalf of the Italian Melanoma Intergroup (IMI), Mar 2 2018, In : Frontiers in Immunology. 9, MAR, 403.Research output: Contribution to journal › Comment/debate
Conflict of Interest
Melanoma
Survival
Italy
Genes
3
Citations
(Scopus)
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab
Italian Melanoma Intergroup (IMI), Jul 1 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.Research output: Contribution to journal › Letter
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab
Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Carosio, R., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Ascierto, P. A., Madonna, G., Simeone, E., De Galitiis, F., Antonini Cappellini, G. C., Marchetti, P., Guida, M., Tommasi, S., Ghilardi, L., Merelli, B., Fava, P. & 7 others, , 2018, In : European journal of cancer. 97, p. 59-61 3 p.Research output: Contribution to journal › Article
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab
Italian Melanoma Intergroup (IMI), Jul 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.Research output: Contribution to journal › Article